Back to Browse Journals » OncoTargets and Therapy » Volume 6

Antitumor effects and mechanisms of dendritic cells stimulated by sCD40L on ovarian cancer cells in vitro

Authors Zhang ZM, Yang XM, Zhang C, Zhang MJ, Li X, Zhang FH, Kang S, Wang SJ, Shan BE

Published Date May 2013 Volume 2013:6 Pages 503—515

DOI http://dx.doi.org/10.2147/OTT.S40504

Received 19 November 2012, Accepted 4 February 2013, Published 6 May 2013

Zheng-mao Zhang,1 Xue-mei Yang,1 Chao Zhang,2 Min-jie Zhang,1 Xia Li,1 Feng-hua Zhang,3 Shan Kang,1 Shi-jie Wang,4 Bao-en Shan2

1Department of Gynecology and Obstetrics, Fourth Hospital of Hebei Medical University, 2Research Center, Fourth Hospital of Hebei Medical University, 3Department of General Surgery, Hebei General Hospital, 4Department of Gastroscopy, Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China

Objective: This study aimed to examine the expression of immune suppression factors and the mechanisms of antitumor effects of cord blood dendritic cells (DCs) stimulated by soluble cluster of differentiation 40 ligand (sCD40L) and cytokines in vitro in ovarian cancer patients.
Methods: The expression levels of interleukin (IL)-10 and transforming growth factor (TGF)-β messenger RNA in peripheral blood were detected by reverse transcription polymerase chain reaction; expression levels of CD80 and CD86 in DCs stimulated by sCD40L were detected using flow cytometry and confocal laser scanning microscopy.
Results: Expression levels of IL-10 and TGF-β genes in the peripheral blood of ovarian cancer patients were significantly increased compared with patients with benign ovarian tumors (P < 0.05). The expression levels of CD80 and CD86 in DCs cultured in the granulocyte-macrophage colony-stimulating factor + IL-4 + stem cell factor + Flt-3 ligand + sCD40L group were significantly increased compared with those in the control group, as assessed by flow cytometry and confocal laser scanning microscopy (P < 0.05).
Conclusion: A variety of cytokines in combination with sCD40L can promote the proliferation of cord blood-derived DCs and induce their maturation as well as stimulating a specific antitumor response.

Keywords: antitumor response, cytokine, immunotherapy, cord blood, IL-10, TGF-β

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma

Luo J, Chen M, Huang H, Yan T, Zhang M, Zhang K, Deng S

OncoTargets and Therapy 2013, 6:577-583

Published Date: 22 May 2013

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer

Berardi R, Santoni M, Morgese F, Ballatore Z, Savini A, Onofri A, Mazzanti P, Pistelli M, Pierantoni C, De Lisa M, Caramanti M, Pagliaretta S, Pellei C, Cascinu S

OncoTargets and Therapy 2013, 6:563-576

Published Date: 21 May 2013

New dilemmas in small-cell lung cancer TNM clinical staging

Zarogoulidis K, Latsios D, Porpodis K, Zarogoulidis P, Darwiche K, Antoniou N, Hohenforst-Schmidt W, Eleftheriadou E, Boutsikou E, Kontakiotis T

OncoTargets and Therapy 2013, 6:539-547

Published Date: 16 May 2013

Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer

Chen XH, Li ZQ, Peng H, Jin SM, Fu HQ, Zhu TC, Weng XG

OncoTargets and Therapy 2013, 6:527-530

Published Date: 14 May 2013

Interleukin-12 prevents colorectal cancer liver metastases in mice

Shen F, Li JL, Cai WS, Zhu GH, Gu WL, Jia L, Xu B

OncoTargets and Therapy 2013, 6:523-526

Published Date: 13 May 2013

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma

Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA

OncoTargets and Therapy 2013, 6:531-538

Published Date: 10 May 2013

PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma

Zhang L, Shi L, Zhao X, Wang Y, Yue W

OncoTargets and Therapy 2013, 6:497-502

Published Date: 7 May 2013

Skin-protective effects of a zinc oxide-functionalized textile and its relevance for atopic dermatitis

Wiegand C, Hipler U-C, Boldt S, Strehle J, Wollina U

Clinical, Cosmetic and Investigational Dermatology 2013, 6:115-121

Published Date: 6 May 2013

Bosutinib in the management of chronic myelogenous leukemia

Keller-von Amsberg G, Schafhausen P

Biologics: Targets and Therapy 2013, 7:115-122

Published Date: 6 May 2013